Actinium Pharmaceuticals Competitors

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and Homology Medicines (NASDAQ:FIXX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Actinium Pharmaceuticals and Homology Medicines, as provided by MarketBeat.

Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. Homology Medicines has a consensus price target of $28.3750, suggesting a potential upside of 200.58%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Homology Medicines.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and Homology Medicines' top-line revenue, earnings per share and valuation.

Actinium Pharmaceuticals has higher earnings, but lower revenue than Homology Medicines.

Profitability

This table compares Actinium Pharmaceuticals and Homology Medicines' net margins, return on equity and return on assets.

Volatility and Risk

Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Homology Medicines has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500.

Insider & Institutional Ownership

17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Homology Medicines shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 33.4% of Homology Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Homology Medicines beats Actinium Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Actinium Pharmaceuticals and Applied Therapeutics, as provided by MarketBeat.

Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. Applied Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 280.21%. Given Actinium Pharmaceuticals' higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Applied Therapeutics.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and Applied Therapeutics' top-line revenue, earnings per share and valuation.

Profitability

This table compares Actinium Pharmaceuticals and Applied Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Insider & Institutional Ownership

17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of Applied Therapeutics shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 31.5% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Actinium Pharmaceuticals beats Applied Therapeutics on 5 of the 8 factors compared between the two stocks.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Actinium Pharmaceuticals and Puma Biotechnology, as provided by MarketBeat.

Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. Puma Biotechnology has a consensus price target of $12.50, suggesting a potential upside of 19.27%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Puma Biotechnology.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and Puma Biotechnology's top-line revenue, earnings per share and valuation.

Actinium Pharmaceuticals has higher earnings, but lower revenue than Puma Biotechnology.

Profitability

This table compares Actinium Pharmaceuticals and Puma Biotechnology's net margins, return on equity and return on assets.

Volatility and Risk

Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.

Insider & Institutional Ownership

17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Puma Biotechnology shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 21.2% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Actinium Pharmaceuticals beats Puma Biotechnology on 6 of the 11 factors compared between the two stocks.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Actinium Pharmaceuticals and RAPT Therapeutics, as provided by MarketBeat.

Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. RAPT Therapeutics has a consensus price target of $40.80, suggesting a potential upside of 137.76%. Given Actinium Pharmaceuticals' higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than RAPT Therapeutics.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and RAPT Therapeutics' top-line revenue, earnings per share and valuation.

Profitability

This table compares Actinium Pharmaceuticals and RAPT Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500.

Insider & Institutional Ownership

17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 65.0% of RAPT Therapeutics shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 31.0% of RAPT Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

RAPT Therapeutics beats Actinium Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and Athenex (NASDAQ:ATNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Actinium Pharmaceuticals and Athenex, as provided by MarketBeat.

Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. Athenex has a consensus price target of $16.2857, suggesting a potential upside of 261.90%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Athenex.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and Athenex's top-line revenue, earnings per share and valuation.

Actinium Pharmaceuticals has higher earnings, but lower revenue than Athenex.

Profitability

This table compares Actinium Pharmaceuticals and Athenex's net margins, return on equity and return on assets.

Volatility and Risk

Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Athenex has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 57.7% of Athenex shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 16.3% of Athenex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Actinium Pharmaceuticals beats Athenex on 6 of the 11 factors compared between the two stocks.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Insider & Institutional Ownership

17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 61.3% of Aldeyra Therapeutics shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 15.0% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Actinium Pharmaceuticals and Aldeyra Therapeutics, as provided by MarketBeat.

Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. Aldeyra Therapeutics has a consensus price target of $26.4444, suggesting a potential upside of 148.07%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Aldeyra Therapeutics.

Volatility and Risk

Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and Aldeyra Therapeutics' top-line revenue, earnings per share and valuation.

Profitability

This table compares Actinium Pharmaceuticals and Aldeyra Therapeutics' net margins, return on equity and return on assets.

Summary

Aldeyra Therapeutics beats Actinium Pharmaceuticals on 6 of the 9 factors compared between the two stocks.